Cervical total disc replacement (cTDR) is still considered a developing technology, with widespread clinical use beginning in the early 2000s. Despite being relatively new to the marketplace, the literature surrounding cTDR is abundant. We conducted a thorough review of literature published in the United States (US) and outside the US to report the current global state of cTDR research and clinical use. Search criteria were restricted to publications with a clinical patient population, excluding finite element analyses, biomechanical studies, cadaver studies, surgical technique-specific papers, and case studies. US publications mostly encompass the results of the highly controlled Food and Drug Administration Investigational Device Exemption trials. The predominantly level I evidence in the US literature supports the use of cTDR at 1 and 2 surgical levels when compared to anterior cervical discectomy and fusion. In general, the outside the US studies typically have smaller patient populations, are rarely controlled, and include broader surgical indications. Though these studies are of lower levels of evidence, they serve to advance patient indications in the use of cTDR. Complications such as secondary surgery, heterotopic ossification, and adjacent segment degeneration also remain a focus of studies. Other external challenges facing cTDR technology include regulatory restrictions and health economics, both of which are beginning to be addressed. Combined, the evidence for cTDR is robust supporting a variety of clinical indications.
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Cervical total disc replacement, Cervical disc, Arthroplasty, Cervical total disc arthroplasty www.neurosurgery-online.com E xperience with cervical total disc replacement (cTDR) began as early as 1966, with Ulf Fernstrom implanting a stainless steel ball bearing device in Sweden. More than 250 patients were implanted with the device-approximately 75 in the cervical spine-but high failure rates led the industry back to fusion.
1,2 cTDR returned in 1989 in Bristol, UK, with a design by Cummins, a stainless steel metal on metal ball, and socket device with anchoring screws. After experiencing
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ACDF, anterior cervical discectomy and fusion; CASP, clinical adjacent segment pathology; cTDR, cervical total disc replacement; FDA, Federal Drug Administration; HO, heterotopic ossification; IDE, Investigational Device Exemption; NDI, Neck Disability Index; OUS, outside the US; QALY, quality-adjusted life year; RASP, radiographic adjacent segment pathology; ROM, range of motion; VAS, visual analog scale; US, United States high failure rates, a redesign was performed and it was re-released as the Frenchay cervical disc, with improved clinical outcomes. 3, 4 Medtronic ultimately purchased the Frenchay disc and it was renamed as Prestige (Medtronic Inc, Dublin, Ireland). In the United States (US) in 1992, Vincent Bryan designed the Bryan disc (Medtronic Inc), with 2 titanium alloy endplates and a polyurethane core filled with saline. 5 The introduction of Prestige and Bryan discs began the next generation of cTDR devices worldwide.
The current published literature for cTDR is widespread throughout the world, with a variety of discs, study designs, and outcome measures. To better understand the vast differences in the type of literature being published in the various regions, the differences in regulatory requirements in these regions must be addressed. Regulatory requirements in the US are governed by the Federal Drug Administration (FDA), and are quite rigid. The FDA requires that cTDR devices undergo an Investigational Device Exemption (IDE) clinical trial. 6 The IDE trial is a multicenter, prospective, controlled clinical trial producing level I evidence for approval. The abundance of level I evidence on cTDR published in the US is largely attributed to the requirements of the FDA to obtain these data for market approval.
Regulatory requirements outside the US (OUS) vary by region, but generally the requirements are less stringent than the FDA requirements. A recent review 7 comparing the Conformite Europeenne mark in Europe to FDA approval noted that Europe's approval process was developed to foster innovation, while the FDA was established to stop unproven devices from reaching the public. The different objectives between these agencies leads to European cTDRs receiving approval through the use of predicate devices, with an average approval time 3 yr faster than in the US. 7 While the use of predicate devices for OUS approval has also led to a wider range of cTDRs available, the evidence for these devices is generally inferior compared to devices approved in the US.
Aside from the different studies for regulatory approval processes, studies from around the world strive to answer very different research and clinical questions. US IDE studies were specifically designed to analyze safety and effectiveness. However, given the robustness of the data sets, multiple post hoc analyses have been conducted on the data, including health economics, complications, and patient selection. OUS studies have been conducted to analyze effectiveness, complications, expanding indications, and patient selection. Here we collected publications from the US and OUS to report the current state of cTDR.
METHODS
A literature search was completed using Pubmed for journal publications related to cTDR. Results were restricted to English only publications. All publications with a clinical patient population receiving implantation of a cTDR were included, while any publications related to finite element analyses, biomechanical studies, cadaver studies, surgical technique-specific papers, and case studies were not included. Publications were categorized by location, with studies performed in the US separated from studies performed OUS. For this report, the US IDE publications are presented in chronological order, while subset analyses are presented by topic. Since the OUS data encompass many different countries, the timelines are disjointed. Therefore, the OUS data are presented by device and topic for congruency.
US Experience

FDA IDE Clinical Trial Approvals and Indications
The process for cTDR approval in the US is the IDE trial. The IDE process requires a noninferiority, prospective, controlled, multicenter trial. On FDA approval, indications, contraindications, warnings, and precautions are approved and published for each device on the FDA website.
There Figure E) . The Mobi-C and Prestige LP include approval for 1-and 2-contiguous level cervical disc disease, while the other devices are approved for 1-level indications only. [8] [9] [10] [11] [12] [13] [14] [15] [16] Figure F ) and M6-C (Spinal Kinetics Inc, Sunnyvale, California; Figure G) , are currently active in the IDE process. Table 1 reports all US FDA-approved devices with manufacturer information, approval dates, number of enrolled patients, and the most recent follow-up data published.
US Clinical Trials
The published outcomes from the US clinical cTDR trials can be separated into 2 groups: the full IDE trial analysis or a subset analysis/partial cohort analysis. The full IDE analysis consists of the prospectively planned clinical, radiographic, and adverse event outcomes for are reported for the entire patient cohort ( Table 2 ). The subset analysis or partial cohort analysis may be a retrospective/prospective study, or it could be a post hoc analysis of data from an IDE trial. Tables 3 and 4 present the subset data from US FDA IDE trials and non-FDA trials, respectively.
US FDA IDE Trials Review
Despite the fact that these cervical arthroplasty devices are made from relatively disparate biomaterials and have differing biomechanical properties, they have been found to be at least noninferior, and have consistently shown superiority on various measures, compared to anterior cervical discectomy and fusion (ACDF). Mummaneni et al 17 published the data on 541 patients at 32 sites leading to the approval of the Prestige-ST disc (Medtronic Inc). They reported a statistically greater rate of neurological success in the arthroplasty group (93%-84%). 17 Heller et al 18 demonstrated statistically greater overall success (83%-73%) as well as statistically greater improvement in Neck Disability Index (NDI) for the Bryan Disc (Medtronic Inc) over 463 patients randomized at 30 sites. Murrey et al 19 reported the results of 209 patients at 13 sites and found statistically significant fewer secondary surgeries for Prodisc-C (Johnson and Johnson) compared to ACDF (1.8% vs 8.5%). 19 Coric et al 20 reported on 98 patients from a single site with 3 different cTDR devices compared to fusion. Cervical arthroplasty showed statistically superior overall success, 85% to 70%, despite a 97% fusion rate in the ACDF group. Coric et al 21 reported a statistically greater overall success for the Kineflex/C (SpinalMotion Inc, 85%-71%) in 279 patients compared to ACDF. Phillips et al 22 showed that PCM (Medtronic Inc) disc patients had statistically significant superior rate of overall success (75%-65%) as well as statistically significant greater improvement in NDI scores and patient satisfaction in 342 patients. Vaccaro et al 23 demonstrated statistically significant superior overall success rate as well as statistically significant fewer secondary surgeries at index level for Secure-C (Globus Medical Inc) compared to ACDF. 23 Two separate studies, involving 339 and 260 patients, respectively, led to the approval of Mobi-C (Zimmer Biomet) for 1-and 2-level cervical radiculopathy. The superiority of cTDR over ACDF was even more pronounced in the 2-level study at 5-yr follow-up, showing a statistically significant percentage of overall success for Mobi-C (61%) versus fusion patients (31%). 24, 25 There were also 2 separate studies leading to the 1-and 2-level approval for Prestige LP (Medtronic Inc). Lanman et al 26 reported statistically significant higher Early criticism of the literature reporting the 2-yr results of IDE studies concentrated on the lack of long-term follow-up. Several peerreviewed published reports have addressed this shortcoming with longterm follow-up. [25] [26] [27] [28] [29] [30] Burkus et al 27 published the 5-yr follow-up results on the clinical and radiographic outcomes of the Prestige ST disc (Medtronic Inc). They showed statistically significant higher rate of NDI improvement at 3 and 5 yr as well as a statistically significant lower rate of index level surgery at 5 yr for cTDR. 27 A 7-yr follow-up from the same group (Burkus, 2014 28 ) showed statistically lower rate of adjacent-level reoperation for Prestige-ST (Medtronic Inc; 4.6% vs 11.9%). Delamarter et al 29 and Zigler et al 30 reported the 4 and 5-yr results, respectively, for Prodisc-C (Johnson and Johnson). They demonstrated statistically significant higher rate of visual analog scale (VAS) satisfaction at all timepoints for cTDR out to 4 yr. Four (3% vs 11%) and 5 (2.9% vs 14.5%) yr reoperation rates were also significantly lower for artificial discs. 29, 30 Recently, Radcliff et al 25 reported the results of Mobi-C disc (Zimmer Biomet) vs ACDF for 2-level cervical disease at 5-yr follow-up and found that artificial disc had statistically significantly greater improvement in NDI, Short form -12 (SF-12), and overall patient satisfaction as well as lower reoperation rate (4.3% vs 16%).
Several meta-analyses have examined the results of studies comparing cervical arthroplasty to fusion. Upadhyaya et al 31 compiled a metaanalysis of the completed data sets from the first 3 FDA-approved IDE studies that evaluated 1213 total patients. They reported statistically significantly lower rate of total secondary surgeries (3.1% vs 8.2%) as well as lower adjacent-level reoperation rate for cTDR. 31 McAfee et al 32 reported a meta-analysis of 1205 from 4 IDE trials and demonstrated an overall composite clinical success rate statistically greater for cTDR (77%) compared to ACDF (69%). These authors also reported that the fusion patients were 148% more likely to undergo a second surgical procedure. 32 The US IDE publications were reviewed to compare outcomes across devices at 2 yr and at the latest timepoint available in published literature. Two years was selected because it is the primary endpoint for FDA approval, while the latest available was reviewed to report longterm sustainability of the devices. While the outcomes collected in the IDE studies were similar, the outcomes reported vary widely. While all outcomes were reviewed, outcomes with less than 50% of the IDE studies reporting were not included. This includes dysphagia, range of motion (ROM), migration, neurological assessment, heterotopic ossification, and radiographic adjacent segment degeneration. Outcomes through 2 yr and through the latest available timepoint are reported in Tables 5  and 6 .
Subset cTDR Analyses Review
Given the regulatory and health insurance landscape in the US, the specific indications approved by the FDA largely dictate clinical usage in the US. The robust data from the IDE trials as well as the high cost of large, prospective trials in the US have led to a paucity of postmarket literature on cTDR. However, there are post hoc, subset analyses performed on data from IDE studies and retrospective databases. These subset analyses are valuable as they allow for a deeper look into specific outcomes, complications, durability of outcomes across multiple cTDR designs, predictive variables for patient outcomes, and much more.
Radiographic Adjacent Segment Pathology and Clinical Adjacent Segment Pathology
There is strong evidence, both biomechanical and clinical, indicating that cervical arthroplasty decreases adjacent-level stresses as well as the rate of radiographic adjacent segment pathology (RASP). 20, 33, 34, 35, [36] [37] [38] [39] [40] [41] [42] RASP is identified as radiographic evidence of degeneration at the adjacent level, while adjacent-level symptoms or operations correlated to RASP indicate the existence of clinical adjacent segment pathology (CASP). While there is little debate that the rate of RASP is significantly higher in ACDF when compared to cTDR, CASP continues to be debated. There is growing evidence, gleaned from long-term follow-up studies and meta-analyses, to suggest that cTDR may lower the incidence of clinical adjacent-level reoperation. 31, 32, [43] [44] [45] However, Nunley et al 46 reported that the incidence of CASP was 15.5% in 167 patients over 51 mo, much lower than the RASP being reported. 46 In a separate study, Nunley et al 47 found that there was no difference in the incidence of CASP between cDTR and ACDF. However, CASP is a multifactorial process that, in addition to type of procedure (ie, arthroplasty vs fusion), may be affected by patient selection, surgical technique, and natural history of underlying disease process. 48 This topic merits further study.
Patient Selection
The FDA approvals largely dictate the indications for cTDR usage in the US. These indications in the US are generally narrower than OUS. There are 2 devices in the US that are indicated for 2 contiguous levels, but none that are approved for greater than 2 levels. Similarly, there is no approved indication for cTDR treatment as a hybrid, adjacent to a previous or concurrent fusion. In 2008, Auerbach et al 49 reported a unique analysis on the US indications/contraindications of cTDR. Using the respective FDA US inclusion/exclusions for Prestige (Medtronic Inc), Prodisc-C (Johnson and Johnson), PCM (Medtronic Inc), and Bryan (Medtronic Inc), the authors analyzed 167 cervical patients for fit into 1 of 3 categories. The categories were (1) patients with direct contraindications, (2) qualified cTDR patients, or (3) qualified patient if indications were expanded to include CASP. Results included 95/167 patients that were contraindicated, with greater than 2 operative levels as the most common exclusion criteria (47 patients). Of these 95 patients, 7 would have qualified if CASP was included as an indication. The remaining 72/167 patients were qualified to receive a cTDR. It is noteworthy that the IDE clinical trial for the PCM cTDR allowed 2 unique criteria: pathology between C3-T1 and prior cervical fusion adjacent to the index level. While multiple other studies allowed a prior cervical fusion, PCM was the only study to allow a prior adjacent-level fusion. 8, 9, 12, 13, 15, 16 There were limited patients who received implantation of the PCM cTDR adjacent to a prior fusion, so analysis and statistics were limited. In 2009, 1-yr results of patients with a prior adjacent fusion were compared to patients without an adjacent fusion. The clinical outcomes between the 2 groups were similar, while there were more reoperations in the adjacent to fusion group, the rates remained low. There were some statistically significant radiographic differences in ROM for the adjacent to ACDF group, but the differences were not significantly outside the preoperative values. 50 Although PCM did ultimately receive approved FDA indications for treatment between C3-T1, the labeling included the same precaution as all other cTDRs against implantation adjacent to a prior fusion. [51] [52] [53] [54] [55] [56] [57] [58] [59] Current indications for cTDR include skeletally mature patients with cervical radiculopathy and/or myelopathy at a single or 2 contiguous levels without severe facet joint degeneration, segmental instability, kyphosis, or neck pain only.
While multilevel (>2 levels) and hybrid treatment seem like logical next steps, there is currently no FDA IDE trial in progress for this approval.
Secondary Surgery
IDE trials are specifically designed to capture data that might otherwise be under-reported in clinical practice. While the FDA IDE trials included specific protocols for evaluating and categorizing secondary surgeries, the categories have been criticized for a lack of transparency. The rates of secondary surgery are well reported with cTDR patients experiencing significantly fewer secondary surgeries than 63 published a post hoc analysis of the Mobi-C (Zimmer Biomet) IDE (1 and 2 levels) reporting the specific symptoms and treatments in addition to the overall rates of secondary surgery for cTDR and ACDF. It was found that the rate of secondary surgery at the index level and the adjacent level were significantly higher for ACDF patients. The most common symptom associated with the secondary surgery was unresolved radiculopathy with neck pain. 63 Nandyala et al 64 used the Nationwide Inpatient Sample database to analyze the rates epidemiology, perioperative complications, and costs differences between cTDR and ACDF reoperations for 1 and 2 levels. Between 2002 and 2011, there were 3536 ACDF revisions and 256 cTDR revision surgeries. cTDR revision surgeries were significantly longer, more expensive, and included a significantly higher incidence of perioperative wound infection when compared to ACDF. 64 Similarly, Bhashyam et al 65 used the 2013-2014 American College of Surgeons National Surgical Quality Improvement Program database to compare 30-d readmission and reoperation rates between 1-level cTDR and ACDF. Among 5590 ACDF and 487 cTDR patients, 2.6% and 0.4% (P = .003) respectively were readmitted, but reoperation rates were not significantly different between the groups. 65 Chang et al 66 reviewed published literature to report reoperation rates due to CASP between cTDR and ACDF. The authors found that CASP reoperation rates were 6.0% for ACDF and 3.1% for cTDR patients. 66 Reoperation rates reported here are within range of level I evidence reported within the IDE trials.
Metal on Metal Construct
The US concern of metal on metal implants led to the analysis and publication of serum titanium concentrations in blood following a metal on metal cTDR. While the authors report significantly higher serum titanium concentrations after surgery with a metal on metal cTDR compared to preoperative values, the concentrations remain lower than in patients receiving the long accepted procedure of posterior spinal instrumentation. The authors concluded that metal on metal cTDR is unlikely to pose an increased risk In vivo. 67 
Heterotopic Ossification
Heterotopic ossification (HO) remains an unintended outcome of cTDR treatment, specifically grade 4 HO. Grade 4 HO represents a full bridging bone across the disc space with little to no remaining motion (<1
• ) at the segment. Rates of HO have been reported with the IDE publications, and grade 4 HO rates are reported as high as 13%. 25, [60] [61] [62] The cTDR IDE publications offer little insight into the mechanism that causes HO, and little is understood about risk factors for development. Outside of the IDE publications there is little US literature that analyzes HO.
Health Economics
FDA approval of cTDR in the US was only the first step to reaching patients. Health economics in the US is driven by insurance coverage, and it can be a challenge to gain coverage following FDA approval. Based on the success of cTDR in clinical trials and the challenges with insurance reimbursement, recent analyses and publications have begun to focus on the cost-effectiveness of cTDR when compared to ACDF.
Ament et al 68 reported that the cost-effectiveness ratio of cTDR compared to ACDF at 2 yr for 2-level disease was $24 954/qualityadjusted life year (QALY), well below the traditionally used threshold of $50 000 per QALY. 68 McAnany et al 69 in the same year utilized a similar model to Ament using 5-yr outcomes. While both treatments were costeffective, cTDR was the dominant strategy. They found that the cTDR cost-effectiveness ratio was $35 976/QALY compared to $42 618/QALY for ACDF. 69 In 2015, Radcliff et al published 2 additional studies on costs of cTDR. 70, 71 The first was a retrospective review of administrative data from the Blue Health Intelligence Database of 6635 ACDF patients 
<.001
Prodisc-C and 327 cTDR patients. They found that by 36 mo the total costs paid by insurers for cTDR were $34 979 vs $39 829 for ACDF. The differences in cost were driven by readmissions and reoperations, which were higher for ACDF patients. 70 The second publication utilizing 7-yr data and a variety of cost analyses found that cTDR continued to be the costeffective treatment over ACDF for a large range of scenarios. 71 There are currently 2 cTDR devices actively in the US FDA IDE regulatory process. The M6-C (Spinal Kinetics Inc) device that has completed enrollment in a 1-level study. This disc features both annular (polyethylene weave) and nuclear components (viscoelastic polyurethane core) that allow for axial compression with independent angular motions in flexion and extension, lateral bending, and axial rotation. The Simplify Disc (SimplifyMedical Inc), which is actively enrolling independent 1-and 2-level IDE studies, is composed of novel biomaterials with poly-ethyl-ethyl-ketone endplates and a self-centering, mobile ceramic core.
OUS Experience
OUS Device Approvals
The cTDR has been approved and marketed OUS since 2000 (Table 7 ), 7 yr earlier than the first US approval, yet the number of publications OUS compared to US is not substantially different. As previously discussed, due to the regulatory environment, OUS literature is generally a lessor level of evidence when compared to publications from the US. However, OUS studies are able to "push the envelope" for patient selection and treatment when compared to US studies.
OUS Prospective Studies Review
OUS studies can vary widely in design and objectives, and span more than 17 yr with the first device approved in 2000. Noteworthy studies and results are presented below sorted by cTDR device, and a thorough list of publications is presented in Table 8 .
Bryan
Several OUS prospective studies using the Bryan cervical disc (Medtronic Inc) analyzed similar clinical and radiographic outcomes to US studies, while utilizing a variety of inclusion/exclusion criteria.
A 2012 study by Zhang et al 72 in China enrolled patients in a prospective study using the same inclusion/exclusion as the US FDA IDE trial. Sixty patients were treated with the Bryan cervical disc, and 60 were treated with ACDF. The authors concluded that the outcomes were favorable for cTDR and comparable to the US trial. However, the strict inclusion/exclusion of an US FDA IDE trial is not typical of OUS studies.
Another Chinese study in 2013 73 prospectively enrolled 20 patients for treatment with a Bryan disc at 1 or 2 levels. However, the 2-level treatment was not restricted to contiguous levels, as is common in the US trials. Four-year clinical outcomes were favorable, with no serious complications. Yet, Zhao et al 74 also in China prospectively enrolled 48 patients for treatment with Bryan at 1, 2, or 3 levels with a high rate of HO reported, 69.0%. The authors report good clinical outcomes through 10 yr, but do not provide insight for the high HO rates.
The Bryan disc was used in multicenter, prospective study in Europe with 89 patients enrolled and treated at a single level with 72 available for 10-yr follow-up. Authors report good clinical outcomes, HO rate of 18%, and reoperation rate for CASP in 6% of patients. 
Prodisc-C
Prodisc-C (Johnson and Johnson) is approved in different regions with variations in name and design including Prodisc-C, Prodisc-C Vivo, and Prodisc-C Nova, but will all be reviewed here simply as Prodisc-C.
Two separate studies prospectively enrolled 1-level patients in Germany in the mid-2000s and reported 1-yr follow-up. The first study included 25 cTDR randomized with an ACDF control of 24 patients. Clinical outcomes were good for both the cTDR and ACDF patients with no statistical differences between the groups. 76 The second study enrolled 27 cTDR with no control group. The clinical results were good, with no reported complications. 78 the results from a single vs multilevel study of the PCM disc with expanded patient indications. Enrollment in the study included patients treated at 1 (n = 72), 2 (n = 53), 3 (n = 12), and 4 (n = 4) cervical levels (not required to be contiguous) between C3-T1. Patients were not excluded for prior cervical fusion surgery, resulting in 11 1-level and 9 multilevel patients treated with PCM as a revision to a failed fusion. Twelve 1-level patients and 9 multilevel patients were treated with PCM adjacent to a prior fusion. Results were significantly improved for both groups, with significantly more improvement in the multilevel cohort. 78 HO rates were reported on this cohort at 6-yr follow-up. The authors found that the incidence of HO in this population was low, 7.7%. Higher HO did correlate to loss of motion, but clinical outcomes were not impacted. 79 Also in Brazil, Oliveira et al 80 reported in 2011 CT results of a similar study, specifically analyzing facet degeneration 5-yr postsurgery. Enrollment criteria were similar to the Pimenta study, and patients were operated at 1 (n = 72), 2 (n = 67), 3 (n = 17), and 4 (n = 6) cervical levels (not required to be contiguous) between C3-T1. Patients with previous fusion were not excluded, so PCM could be implanted adjacent to a prior fusion. The data showed that facet stress created by PCM does lead to a small amount of facet joint degeneration, 14% with grade 3 or 4.
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Discover
The Discover disc (Johnson and Johnson) has been used in prospective, controlled trials in China, Croatia, Sweden, and Norway.
A 2014 Chinese study enrolled 1 and 2-level patients using the Discover cervical disc and ACDF. This was a larger scale study, with 149 cTDR (117 1-level and 32 2-level) and 296 ACDF (208 1-level and 88 2-level). Reported clinical results indicate no significant difference between cTDR and ACDF treatment; however, the 2-yr radiographic evidence indicated a significantly higher ROM at the adjacent level in ACDF patients. 81 Also reported in 2014, a Croatian study enrolled 101 patients: 51 treated with Discover and 50 with ACDF at 1-level. The authors reported that patients treated with Discover showed statistically significant better clinical outcomes in VAS and NDI than ACDF patients at 2-yr followup. 82 The results of a Norwegian study were reported in 2016. The data were collected from a prospective, controlled, randomized study, but only the cTDR data were reported for this publication. Thirty-seven patients were treated with the Discover disc at 1-level, and followed for 2 yr. The authors reported 16% of patients with grade 4 HO, and 62% of patients with high-grade ossification (grade 3 or 4). The grade of HO did not impact clinical outcomes in patients. 83 
Mobi-C
The Mobi-C (Zimmer Biomet) has also been studied with expanded patient indications in a large prospective, noncontrolled study in France. This study treated patients at 1 (n = 175), 2 (n = 51), 3 (n = 4), and 4 (n = 1) levels from C3-T1 with outcomes reported through 2 yr. Patients with previous spine surgery, even at the index level, were not excluded from the study. In the 1-level cohort, 21 patients (28 levels) had prior cervical fusions, with 18 of these fusions adjacent to the index level. In the multilevel cohort (2, 3, and 4 levels), 5 patients (5 treated levels) had prior cervical fusions, with 3 adjacent to the index level and 2 fusions at the index level. The authors reported favorable outcomes for both groups, with no significant difference between the 1-level and multilevel groups. 84 A study in China was more conservative with inclusion/exclusion, including patients treated at 1-level with Mobi-C or ACDF. Clinical outcomes at 5 yr were reported to be similar between the groups; however, reoperation rates were significantly higher for the ACDF patients.
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M6-C
M6-C (Spinal Kinetics Inc) was studied in prospective population of 36 patients treated at 1 level. The inclusion/exclusion was strictly controlled, similar to cTDR studies in the US. Results indicate positive changes in all clinical outcomes, as well as no reoperations or serious adverse events. 86 
OUS Retrospective Studies
Unlike the US retrospective database reviews, the OUS retrospective studies include patient data from clinic/hospital records. In addition to access more outcomes than a database, the data collected are more representative of the true use cTDR use in that region.
A retrospective study was conducted in 2006 in Korea. Forty-eight patients were identified with prior treatment with the Bryan disc (Medtronic Inc). 87 Thirty-four patients were treated at 1-level with the Bryan disc, 12 patients were treated with the Bryan disc at 1-level, and a fusion at the adjacent level (hybrid). The mean follow-up was 11.8 mo, with patients reporting improved clinical outcomes. Radiographic outcomes revealed some early postoperative kyphotic changes, but the differences were not significant. 87 A large population of patients was retrospectively reviewed for postoperative dysphagia rates in China and reported in 2016. 88 The retrospective review included 1 and 2-level patients treated with Prestige LP (Medtronic Inc; 138 1-level, 67 2-level) and ACDF (90 1-level, 49 2-level). If patients met eligibility for a cTDR (no cervical instability and no severe cervical osteophytosis), they were allowed to select their treatment. The rates of dysphagia were significantly higher for the ACDF group; however, the authors report that the dysphagia was transient and further study is needed. 88 Baguera-C was the focus of 2 retrospective studies: one in Europe and the other in Korea. The European study reported outcomes from 5 centers in 2016. The retrospective review included 99 patients implanted with Baguera-C (Spineart Inc, Geneva, Switzerland) and followed for 2 yr. Surgeries included 60 patients with 1-level, 30 with 2-level, and 9 with 3-level. A hybrid approach with ACDF was used in 18 of these cases, with 12 hybrids at 2 levels and 6 hybrids at 3 levels (2 fusions and 1 disc). Results of the study were radiographic only, with the authors finding no significant differences in postoperative changes in radiographic measures. Grade 3 and 4 HO was observed in 19.3% of patients. 89 The study in Korea reported 2-yr follow-up of patients treated at 1-level with Baguera-C. The focus of this study was bone loss following surgery with cTDR, which the authors feel is a potential complication associated with early postoperative neck pain. The results here indicate that 29 patients experienced bone loss, with 8 patients showing a major change.
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Summary
The published US and OUS data, while similar in some respects, are vastly different in others. The most notable difference is that the level of evidence of clinical trials published in the US is higher quality than OUS, but a better level of evidence study is not the only value in research.
The OUS data provide valuable insight for patient selection and indications that the US has not studied. The OUS data published indicate that cTDR might be viable treatment for many patients who would receive a fusion in the US. This includes multilevel treatment (>2 levels, or noncontiguous) and hybrid treatment, utilizing various combinations of arthroplasty and fusion.
While published clinical outcomes, including pain scores and functional scores, from the US and OUS are favorable for cTDR compared to ACDF, there remains some differences that are not understood. The scale used to measure HO is not consistent throughout all studies, and in the US the highest rate of grade 4 HO, or bridging bone, reported within the IDE publications is 13%. OUS publications report HO rates as high as 69%, but the methods of determination are unclear. Whether the difference is methods driven or has a clinical cause, HO is not well understood in the US or OUS.
cTDR is well established as a treatment worldwide for patients with cervical degenerative disc disease, but clinical trials remain regional in design.
There are few papers that analyze or review literature from a global perspective. Zhang et al 91 published a meta-analysis of 19 randomized, controlled trials involving 4516 total patients from the US and OUS. cTDR showed statistically significantly better functional outcome (NDI), neck pain scores (NRS/VAS), and overall success (composite measures) as well as statistically significantly fewer index (P < .00001) and adjacent (P < .008) level reoperations. 91 While this is a first step in understanding cTDR from a global perspective, Zhang only included OUS studies that utilized similar patient populations to the US IDEs. Our intention for this review is to understand the global landscape of cTDR.
CONCLUSION
The volume of level I and II evidence supporting the efficacy of cTDR is unparalleled in the field of spine surgery. Through approved US FDA IDE trials alone, approximately 2000 cTDRs have been implanted with long-term follow-up since the early 2000s. cTDR has been vetted with extraordinary scrutiny and directly compared to a "gold standard" procedure, ACDF. This evidence-basis has been established through data generated from the multiple prospective, randomized, controlled IDE studies comparing cervical artificial discs to ACDF that ultimately led to FDA approval for 7 devices.
OUS data continue to explore and expand the patient indications for cTDR, including implantation at more than 2 levels, as a hybrid with fusion, and adjacent to a prior fusion. While the US is slower to adopt these expanded patient indications, the OUS studies are leading the way for a larger eligible patient population.
Regulatory restrictions will continue to drive the types of clinical research and the usage of cTDR devices globally, while health economics will continue to drive the postmarket use. cTDR will continue to evolve with expanded indications, increased adoption by surgeons and payors, as well as the introduction of novel devices.
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